Sorrento Therapeutics Inc. has published data on the identification, in vitro binding and neutralizing activity of a novel monoclonal antibody (MAb), STI-5041, against the SARS-CoV-2 WA-1 strain as well as the alpha and beta variants from their G-MAB library screening.
Aim Vaccine Co. Ltd. priced an IPO on the Hong Kong Stock Exchange, raising HK$70.01 million (US$9 million) to fund work on its late-stage vaccine pipeline. Its shares increased only 3.09% on debut Oct. 6 but closed the week at HK$24.80, up 54% over its listing price of HK$16.16.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: ABVC, Annovis, Clarametyx, Crinetics, Eiger, Eli Lilly, Entera, Evofem, Humanetics, Immutep, Kiromic, Nova Mentis, Takeda, Transcenta.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Biomarin, Nektar, Pharmacyte, Puretech, Teva.
The University of Arizona has divulged nonstructural protein 3 (Nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.
CEPI, the Coalition for Epidemic Preparedness Innovations, will provide seed funding of up to $4.8 million to Intravacc BV to advance the development of a broadly protective betacoronavirus vaccine candidate, which can be delivered intranasally.
The U.S. FDA’s device center recently advised companies that make tests for the COVID-19 pandemic that the emergency use authorization program for tests is winding down, albeit with a few exceptions.
Additional early-stage research and drug discovery news in brief, from: CSL, Elicio Therapeutics, Enzolytics, Innovation Pharmaceuticals, Lumen Bioscience, Nanology.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abeona, Aridis, Connect, Kalvista, Kubota, Paradigm, Pfizer, Saol, Synairgen.
Although U.S. President Joe Biden suggested in September that the pandemic is over, health officials insist there is still much to do in preparation for an endemic stage of the SARS-CoV-2 virus. The number of weekly COVID-19 confirmed cases both globally and in the U.S. is similar with each of the last two years, but deaths from the virus are at some of the lowest levels since the pandemic began. Still, the virus will continue to evolve and circulate, and the biopharma industry will need to develop new booster vaccines, antivirals and monoclonal antibodies, among other candidates, to prepare for upcoming battles.
RSS
